Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.47 USD
+0.09 (6.52%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.48 +0.01 (0.68%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
PACB 1.47 +0.09(6.52%)
Will PACB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PACB
Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks
Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
PacBio's (PACB) New Panel to Aid Its Clinical Research Solution
Other News for PACB
Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday
APEV, PACB and BILI are among premarket gainers
Cisco downgraded, Lucid resumed: Wall Street's top analyst calls
PacBio moved to Neutral at JPMorgan after guidance cut
PacBio just downgraded at JPMorgan, here's why